Niacinate
"No-Flush" Niacin

DESCRIPTION
Niacinate tablets, provided by Douglas Laboratories®, contain inositol hexaniacinate which provides niacin. This ester of niacin and inositol eliminates the uncomfortable skin-flushing side effects often observed with high-dose crystalline niacin.

FUNCTIONS
Niacin (vitamin B3) occurs in the body as two metabolically active coenzymes, NAD (nicotinamide adenine dinucleotide) and NADP (NAD phosphate).

The niacin coenzymes NAD and NADP have pervasive roles in energy-related and biosynthetic metabolic processes. At least 200 enzymes depend on these niacin cofactors. The NAD-dependent enzymes are involved in mostly catabolic, oxidative reactions that release energy from carbohydrate, fat, and protein, whereas the NADP-dependent enzymes more commonly function in biosynthesis of such compounds as fatty acids and steroid hormones.

Independent of its functions as NAD or NADP, niacin is also involved in the regulation of normal blood lipoprotein and cholesterol levels, and the maintenance of normal vascular tone.

Dietary niacin is generally well absorbed and taken up by the liver. Any excess niacin is metabolized by the liver and excreted by the kidneys.

Because the liver has a limited capacity to metabolize niacin, high doses of regular, crystalline niacin are often not well tolerated, causing vasodilatory side effects known as skin-flushing and itching.

INDICATIONS
Niacinate tablets may be a useful dietary supplement for individuals who wish to increase their intake of niacin without the uncomfortable side effects of skin flushing.

FORMULA (NCT)
Each tablet contains:
Niacin .....505 mg
(as inositol hexaniacinate)
Inositol ..... 115 mg
(from inositol hexaniacinate)

Other ingredients: Dicalcium phosphate, cellulose, stearic acid, silica and vegetable stearate.

SUGGESTED USE
One to three tablets daily with meals, or as directed by a healthcare professional.

SIDE EFFECTS
No adverse side effects have been reported.

STORAGE
Store in a cool, dry place, away from direct light. Keep out of reach of children.

Niacinate

"No-Flush" Niacin

REFERENCES

Aylward M. Hexopal in Raynaud's disease. J Int Med Res 1979;7:484-491.
Canner PL et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.
Colletti RB et al. Niacin treatment of hypercholesterolemia in children. Pediatrics 1993;92:78-82.
Holti G. An experimentally controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud's phenomenon. J Int Med Res 1979;7:473-483.
O'Hara J et al. The therapeutic efficacy of inositol nicotinate (Hexopal®) in intermittent claudication: a controlled trial. Brit J Clin Pract 1988;42:377-383.
Probstfield JL. Nicotinic acid as a lipoprotein-altering agent: therapy directed by the primary physician. Arch Int Med 1994;154:1557-1559.
Sunderland GT et al. A double blind randomized placebo controlled trial of hexopal in primary Raynaud's disease. Clin Rheumatol 1988;7:46-49.

For more information on Niacinate visit douglaslabs.com

† These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.

Manufactured by
Douglas Laboratories
600 Boyce Road
Pittsburgh, PA 15205
800-245-4440
douglaslabs.com

You trust Douglas Laboratories.
Your patients trust you.